GLP2T is a dual GLP-1 and GIP receptor agonist studied for its synergistic effects on glucose control and weight management.

Research Focus:

• Type 2 diabetes research
• Weight loss and obesity management
• Insulin sensitivity enhancement
• Cardiometabolic risk reduction

Sources:

SURMOUNT-1 weight-loss (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

SURPASS glycemic control (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2107519

Dual agonism rationale (Nature Reviews Endocrinology): https://www.nature.com/articles/s41574-022-00728-6

⚠️ Disclaimer: For research use only. Not intended for human consumption. This information is provided for educational purposes and has not been evaluated by the FDA.